Foghorn Therapeutics

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

Foghorn has partnering deals with major big pharma. They have a novel technology which no one else seems to have.

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced management's participation in the following investor conferences. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics Announces Upcoming Investor Conference Participation

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ: FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).  The FDA initiated the partial clinical hold.

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced the Food and Drug Administration (FDA) has placed the Phase 1 dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) on a partial clinical hold. The partial clinical hold was initiated by the FDA following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation syndrome is associated with AML/MDS therapeutics that induce differentiation, an effect that is believed to be on-target for the proposed mechanism of action for FHD-286. The FDA has requested a review of the safety database, risk mitigation strategies and a breakdown of clinical activity across dose levels.

Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS

- Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system; both FHD-286 and FHD-609 continue to dose escalate and enroll patients with initial clinical data expected for FHD-286 in H2 2022 and FHD-609 in 2023

Foghorn Therapeutics Provides First Quarter 2022 Corporate Update

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the BRG1 (SMARCA4) and BRM (SMARCA2) dual inhibitor, FHD-286, for the treatment of cancer, at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana. FHD-286 has first-in-class potential and is Foghorn's first candidate directly targeting the chromatin regulatory system to emerge from the Company's Gene Traffic Control® platform. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the company will have an oral and late-breaking poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana. Presentations include preclinical data supporting the clinical development of the novel BAF inhibitor FHD-286 for the treatment of acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) and metastatic uveal melanoma (UM).

Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting

Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?

The average of price targets set by Wall Street analysts indicates a potential upside of 85% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Foghorn Therapeutics Inc. (FHTX) Could Surge 85%: Read This Before Placing a Bet

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate at the 2022 Guggenheim Targeted Protein Degradation Day which is being held virtually on March 16th, 2022. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day

– Initial clinical data for FHD-286 expected in H1'22 and FHD-609 as early as H1'22

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate on a panel at Cowen's 42nd Annual Health Care Conference which is being held virtually March 7th through March 9th, 2022. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate at the Cowen's 42nd Annual Health Care Conference

The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%

Foghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Foghorn Therapeutics Inc. (FHTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bellon, Ph.D., currently Senior Vice President of Drug Discovery, is promoted to Chief Scientific Officer, effective today, January 10, 2022. Carl Decicco, Ph.D., is retiring from his role as Chief Scientific Officer at Foghorn.

Foghorn Therapeutics Announces Chief Scientific Officer Succession

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtually on January 10th through the 13th, 2022. With an initial focus in oncology, Foghorn's Gene Traffic Control Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

The clinical-stage biotech could reap as much as $1.3. billion from a new research and development pact with a heavy-hitting partner.

Why Foghorn Therapeutics Blasted 55% Higher Today

Shares of FHTX stock are surging today after the company announced a partnership with Eli Lilly. Here's what you should know.

FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn Today

Eli Lilly

Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY), and Foghorn Therapeutics Inc (NASDAQ: FHTX) have collaborated to create oncology medicines by applying Foghorn's Gene Traffic Control platform.  The collaboration includes a co-development and co-commercialization agreement for Foghorn's selective BRM oncology program and an additional undisclosed oncology target.

Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly

The stock price of Foghorn Therapeutics Inc. (NASDAQ: FHTX) increased by over 30% pre-market today. This is why it happened.

Foghorn Therapeutics Stock (FHTX): Why The Price Surged Today

INDIANAPOLIS and CAMBRIDGE, Mass. , Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control ® platform.

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma

Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

David Millan, PhD, VP of Chemistry, to present overview of company's proprietary protein degrader platform and its clinical stage asset, FHD-609, a potent and selective heterobifunctional degrader of BRD9 David Millan, PhD, VP of Chemistry, to present overview of company's proprietary protein degrader platform and its clinical stage asset, FHD-609, a potent and selective heterobifunctional degrader of BRD9

Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

News for Foghorn Therapeutics Stock (FHTX)